Abstract
Recent advances in the field of minimally invasive surgery for the treatment of lung cancer and, in particular, the emergence of the uniportal approach alongside the more “traditional” multiportal approach, have generated an interesting debate. Supporters of the two different techniques have been on the field with the intent of trying to determine what is the best approach to offer to their patients to guarantee them, not only the best technical result, but above all the lower functional impact and effective oncological results. This article explores the necessary and rigorous scientific path to be followed to ensure adequate clinical trials to support one or the other technique to try to reach an objective conclusion of the current debate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
